Plasma pentraxin 3, but not high-sensitivity c-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 65 A, Issue 5, 2010, Pages 547-552

  Yano, Yuichiro ^a,b   Matsuda, Shuntaro ^c   Hatakeyama, Kinta ^c   Sato, Yuichiro ^c   Imamura, Takuroh ^d   Shimada, Kazuyuki ^b   Kodama, Tatuhiko ^e   Kario, Kazuomi ^b   Asada, Yujiro ^c  

^a Division of Internal Medicine   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cognitive impairment; Elderly hypertensive patients; High sensitivity C reactive protein; Pentraxin 3

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PENTRAXIN 3; SERUM AMYLOID P;

AGED; ARTICLE; BLOOD; BODY MASS; CAROTID ARTERY; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RISK FACTOR; WEIGHT REDUCTION;

AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID ARTERIES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SERUM AMYLOID P-COMPONENT; WEIGHT LOSS;

EID: 77951907104     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glq030     Document Type: Article

References (31)

1. Aflalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009;103:1616-1621.
2. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American geriatrics Society/national Institute on Aging Research Conference on Frailty in older Adults. J Am Geriatr Soc. 2006;54:991-1001.
3. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54:447-451.
4. Qiu C, Winblad B, Fratiglioni I. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4: 487-499.
5. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, Cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4:371-380.
6. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer lJ. Early infammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174.
7. Engelhart MJ, Geerlings MI, Meijer J, et al. Infammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61:668-672.
8. van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112:900-905.
9. Wright CB, Moon Y, Paik MC, et al. Infammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke. 2009;40:3466-3471.
10. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition\the case for a head-to-toe infammatory paradigm. J Am Geriatr Soc. 2002;50: 2041-2056.
11. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671-674.
12. Hughes TF, Borenstein AR, Schofeld E, Wu Y, Larson EB. Association between late-life body mass index and dementia: the Kame project. Neurology. 2009;72:1741-1746.
13. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R. Measures of adiposity and dementia risk in elderly persons. Arch Neurol. 2007;64: 392-398. (Pubitemid 46425695)
14. Sakakura K, Ishikawa J, Okuno M, Shimada K, Kario K. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. Am J Hypertens. 2007;20:720-727.
15. Kivipelto M, Ngandu T, Fratiglioni L, et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol. 2005;62:1556-1560. (Pubitemid 41434560)
16. Gorospe EC, Dave JK. The risk of dementia with increased body mass index. Age Ageing. 2007;36:23-29.
17. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson gK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22: e10-e14.
18. Mantovani A, Garlanda C, Bottazzi B, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326-330.
19. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471-477.
20. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol. 2007;27:161-167.
21. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107.
22. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:142-161.
23. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852-857.
24. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29: 594-599
25. Suzuki S, Takeishi Y, Niizeki T, et al. Pentraxin 3, a new marker for vascular infammation, Predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008;155:75-81.
26. Tong M, Carrero JJ, Qureshi AR, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, Protein-energy wasting, Cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007;2:889-897.
27. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pen-traxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636-641.
28. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-1222.
29. Chen X, Wen W, Anstey KJ, Sachdev PS. Prevalence, Incidence, and risk factors of lacunar infarcts in a community sample. Neurology. 2009;73:266-272.
30. Ishikawa J, Tamura Y, Hoshide S, et al. Low-grade infammation is a risk factor for clinical stroke events in addition to silent cerebral in-farcts in Japanese older hypertensives: the Jichi Medical School ABPM Study, Wave 1. Stroke. 2007;38:911-917.
31. nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J Hypertens. 2008;26: 1636-1641.